Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16916365 | 0.97 | KDM4E (0.46) | KDM4EGAACYP11B2POLBCASP3 | |
| SCHEMBL61212 | 0.97 | KDM4E (0.46) | KDM4EGAACYP11B2POLBCASP3 | |
| Ammonia Solution, Strong SCHEMBL28326987 | 0.97 | KDM4E (0.41) | KDM4EGAACYP11B2POLBCASP3 | |
| SCHEMBL1444138 | 0.94 | KDM4E (0.38) | KDM4EGAACYP11B2POLBCASP3 | |
| SCHEMBL935722 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL29162507 | 0.86 | OPRL1 (0.36) | KDM4EGAAMAPK1OPRL1OPRM1 | |
| Carbamic Acid SCHEMBL9705391 | 0.83 | KDM4E (0.45) | KDM4EGAACYP11B2POLBCASP3 | |
| Fluoromethane SCHEMBL28832696 | 0.81 | PDE10A (0.34) | KDM4EGAAMAPK1OPRL1OPRM1 | |
| SCHEMBL2103674 | 0.79 | OPRM1 (0.33) | KDM4EGAAOPRL1OPRM1 | |
| SCHEMBL12539825 | 0.77 | MAPK1 (0.50) | MAPK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| CN-105198864-A | Solvent-free preparation method of cyclopentyl pyrimidine compound | HUAREN PHARMACEUTICAL CO LTD | 2015-12-30 | — | — | CN | claimed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | claimed |
| CN-112898210-B | Process for preparing pyrimidinylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-112898210-B | Process for preparing pyrimidinylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| EP-4282973-A3 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-11840539-B2 | Substituted pyrrolo,-furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840539-B2 | Substituted pyrrolo,-furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-2404907-A1 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| CN-102015708-A | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2011-04-13 | — | — | CN | disclosed |
| CN-101932564-A | Hydroxylated pyrimidyl cyclopentanes as the AKT kinases inhibitor | ARRAY BIOPHARMA INC | 2010-12-29 | — | — | CN | disclosed |
| CN-101932565-A | Hydroxylated pyrimidyl cyclopentane as the AKT kinases inhibitor | GENENTECH INC | 2010-12-29 | — | — | CN | disclosed |
| CN-101932565-A | Hydroxylated pyrimidyl cyclopentane as the AKT kinases inhibitor | GENENTECH INC | 2010-12-29 | — | — | CN | disclosed |
| CN-101932564-A | Hydroxylated pyrimidyl cyclopentanes as the AKT kinases inhibitor | ARRAY BIOPHARMA INC | 2010-12-29 | — | — | CN | disclosed |
| US-20100233733-A1 | MULTIPLE MECHANISMS FOR MODULATION OF THE PI3 KINASE PATHWAY | NODALITY, INC., A DELAWARE CORPORATION (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | KDM4E 1635/4885GAA 3180/4885CYP11B2 1433/4885 |
| US-11840539-B2 | Substituted pyrrolo,-furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof | ABCB1, ABCC1, ABCG2 | KDM4E 1977/4885GAA 1307/4885CYP11B2 1779/4885 |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | KDM4E 1873/4885GAA 4116/4885CYP11B2 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.